Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have earned an average recommendation of “Moderate Buy” from the eleven research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $39.75.

A number of analysts recently commented on the stock. HC Wainwright upped their price target on shares of Genmab A/S from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Wall Street Zen raised shares of Genmab A/S from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Genmab A/S in a report on Wednesday, October 8th. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target for the company in a research report on Tuesday, September 23rd. Finally, Truist Financial reissued a “buy” rating and set a $48.00 price objective (down previously from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th.

Hedge Funds Weigh In On Genmab A/S

Hedge funds have recently bought and sold shares of the company. Paradigm Biocapital Advisors LP purchased a new stake in Genmab A/S in the 3rd quarter worth approximately $117,063,000. Orbis Allan Gray Ltd grew its position in shares of Genmab A/S by 38.7% during the 2nd quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock valued at $163,635,000 after purchasing an additional 2,209,659 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Genmab A/S by 152.3% in the second quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock worth $71,367,000 after purchasing an additional 2,084,966 shares during the period. Deep Track Capital LP purchased a new stake in shares of Genmab A/S in the third quarter worth $14,760,000. Finally, ABC Arbitrage SA purchased a new stake in shares of Genmab A/S in the second quarter worth $9,236,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Shares of GMAB opened at $31.82 on Tuesday. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $33.96. The business has a 50-day moving average of $30.96 and a 200 day moving average of $27.38. The firm has a market cap of $20.44 billion, a P/E ratio of 13.54, a price-to-earnings-growth ratio of 2.01 and a beta of 0.90.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.48 by $0.17. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $975.40 million. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. As a group, research analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.